Blood test could revolutionize prostate cancer treatment choices
NCT ID NCT04067713
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study, called PARADIGM, is not testing a new drug. Instead, it looks at whether analyzing DNA from a blood sample can tell doctors which standard treatment—like hormone therapy or chemotherapy—will work best for a patient with metastatic prostate cancer. Researchers will take extra blood samples from 192 participants during their normal care and measure markers like PSA and tumor DNA. The goal is to create a test that personalizes treatment, saving time and avoiding side effects from drugs that won't help.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this blood test could help doctors choose the most effective existing treatment for each patient with metastatic prostate cancer, improving outcomes and avoiding ineffective therapies.
- What could go wrong
- This is an observational study, not a treatment trial. The blood test may not prove accurate enough to guide decisions, and results may take years to confirm.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aberdeen Royal Infirmary
Aberdeen, AB15 6RE, United Kingdom
-
Barts Health NHS Trust, Royal London Hospital
London, E1 1FR, United Kingdom
-
Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust
Doncaster, DN2 5LT, United Kingdom
-
Guy's and St Thomas's NHS Foundation Trust
London, SE1 9RT, United Kingdom
-
Kingston Hospital NHS Foundation Trust
London, KT2 7QB, United Kingdom
-
Medway NHS Foundation Trust
Gillingham, ME7 5NY, United Kingdom
-
Royal Bournemouth Hospital
Bournemouth, BH7 7DW, United Kingdom
-
Royal Free London NHS Foundation Trust
London, NW3 2QG, United Kingdom
-
The Beatson West of Scotland Cancer Centre
Glasgow, G12 0YN, United Kingdom
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
The Clatterbridge Cancer Centre NHS Foundation Trust
Liverpool, CH63 4JY, United Kingdom
-
The Princess Alexandra Hospital NHS Trust
London, CM20 1QX, United Kingdom
-
The Royal Marsden NHS Foundation Trust
London, SW3 6JJ, United Kingdom
-
University College London Hospital
London, W1T 4TJ, United Kingdom
-
University Hospital Southampton NHS Foundation Trust
Southampton, SO16 6YD, United Kingdom
-
Velindre University NHS Trust
Cardiff, CF15 7QZ, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a blast of testosterone shrink hard-to-treat prostate cancer?
- A PET scan and a blood test may predict which men with advanced prostate cancer will benefit from targeted therapy
- New drug ORIC-944 targets Hard-to-Treat prostate cancer
- Precision radiotherapy may buy time for men with spreading prostate cancer
- Mapping Cancer's next move: study tracks where prostate cancer returns after aggressive radiotherapy
- Smart scans may slash radiation doses for metastatic prostate cancer